RxDoctor Payments Data

Harvey Hsu, MD

Internal Medicine · Phoenix, AZNPI 1659330769

Payments from drug & device makers

$502in general payments, 2019–2025

Across 15 payments — averaging $33.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microtransponder, Inc.$161
  • Mallinckrodt Hospital Products Inc.$108
  • Exact Sciences$96
  • Abbott$24
  • The Binding Site Inc.$19
  • Pfizer$18
  • plus $76 from 5 others

What the payments were for

  • Food & beverage$502100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Microtransponder, Inc.1$161
Mallinckrodt Hospital Products Inc.1$108
Exact Sciences5$96
Abbott1$24
The Binding Site Inc.1$19
Pfizer1$18
Johnson & Johnson1$17
Corcept Therapeutics1$15
Novartis1$15
Novo Nordisk1$15
Inspire Medical Systems, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$502 in reported general payments places this provider in the 65th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$68,706
Medicare patients
301
Services billed
788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide92$122,227
JardianceEmpagliflozin87$102,889
MounjaroTirzepatide51$73,735
OzempicSemaglutide70$72,433
EliquisApixaban76$63,600
XareltoRivaroxaban27$25,845
Soliqua 100-33Insulin Glargine/Lixisenatide14$11,664
SymbicortBudesonide/Formoterol Fumarate27$7,925
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$7,735
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$4,877
Atorvastatin Calcium428$3,533
Qvar RedihalerBeclomethasone Dipropionate13$3,213
LantusInsulin Glargine,hum.Rec.Anlog14$3,093
Albuterol Sulfate HfaAlbuterol Sulfate102$2,761
Rosuvastatin Calcium204$2,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$72,43370 claims
PfizerEliquis$18$63,60076 claims
Johnson & JohnsonXarelto$17$25,84527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →